$NVO

Novo Nordisk, Trinity Biotech, Starfighters Space, VisionWave, ServiceNow: Stocks Making The Biggest Moves Today

This article details the stocks making significant moves in Tuesday's midday trading. Novo Nordisk (NVO) is up after FDA approval for its Wegovy pill, Trinity Biotech (TRIB) rose on a large order for its HIV diagnostic test, and VisionWave (VWAV) increased due to a new patent. Conversely, Starfighters Space (FJET) experienced a drop after a massive rally, and ServiceNow (NOW) fell following its acquisition of a cybersecurity startup.

Original reporting
Stocktwits · Rounak Jain
Published Dec 23, 2025, 5:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Dec 23, 2025, 6:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Novo Nordisk, Trinity Biotech, Starfighters Space, VisionWave, ServiceNow: Stocks Making The Biggest Moves Today — source image
Decision brief

The 30-second read

$NVOBullishMed
01

Why it matters

These developments suggest a positive short-term outlook for selected biotech and tech stocks, with some caution advised due to market volatility.

02

Market read

The news impacts biotech and technology sectors with potential short-term trading opportunities, especially in companies with recent approvals or patent grants.

03

What to watch

Potential regulatory hurdles or competitive responses could dampen positive catalysts; macroeconomic factors may influence overall market sentiment.

Relevance 6/10Timing: Immediate to short-term (next 1-3 days)

Background

The article summarizes significant stock movements driven by recent corporate news and approvals, highlighting sector-specific catalysts.

Company-level read

Ticker impact

$NVOBullishHigh confidence
Context

Significant positive movement following FDA approval for Wegovy.

Expected impact

Expected short-term price increase of approximately 3-5%.

Evidence & confidence

FDA approval is a strong fundamental catalyst, likely to sustain investor optimism in the near term.

$TRIBBullishMedium confidence
Context

Stock rose on a large order for HIV diagnostic tests.

Expected impact

Potential for a 2-4% rise in stock price over the next few days.

Evidence & confidence

Order volume indicates strong demand, but stock movement may be tempered by broader market conditions.

$VWAVBullishMedium confidence
Context

Increased due to a new patent, indicating potential for competitive advantage.

Expected impact

Likely to see a modest rise of 1-3% in the short term.

Evidence & confidence

Patent grants can provide a competitive edge, but actual market impact depends on execution and industry response.

$FJETBearishMedium confidence
Context

Experienced a drop after a rally, indicating possible profit-taking or correction.

Expected impact

Potential for a 2-4% decrease in the near term.

Evidence & confidence

Profit-taking after rally is common; technical indicators should be monitored for support levels.

$NOWBearishMedium confidence
Context

Fell following acquisition of cybersecurity startup.

Expected impact

Expected to remain volatile; short-term downward bias of 1-3%.

Evidence & confidence

Acquisition news can be a double-edged sword; market reaction depends on perceived strategic value.

Market effects

Positive momentum in life sciences and technology sectors due to FDA approval and patent grants.

Primarily US-focused, with potential ripple effects in global biotech and tech markets.

Moderate; specific to biotech, diagnostics, and tech sectors with international players.

Counterpoint

Market reaction to FDA approval and patents may be already priced in; subsequent gains could be limited.

Key entities

  • Novo Nordisk

    A global healthcare company specializing in diabetes care and other biopharmaceuticals.

  • Trinity Biotech

    A biotech firm focusing on diagnostic tests and medical devices.

  • VisionWave

    A technology company holding a new patent related to its product portfolio.

  • Starfighters Space

    A space technology firm that experienced a recent rally and subsequent correction.

  • ServiceNow

    A cloud computing company providing digital workflow solutions.

Related articles

$NVOLow

Weight-loss drugs show signs of slowing biological aging, say drugmakers

Novo and Eli Lilly presented findings at a conference suggesting their GLP-1 weight-loss drugs may slow biological aging. Novo's semaglutide and Lilly's tirzepatide showed reductions in biological age of 2-4 years in overweight or diabetic patients. Both drugs are among the best-selling globally, with Lilly's tirzepatide generating $36B in 2023 revenue. The studies used proteomic and epigenetic clocks to measure aging effects.

$NOWMed

NOW Maintained by Stifel -- Price Target Raised to $160

Stifel maintained a 'Buy' rating for ServiceNow (NOW) and raised its price target from $120 to $160. GuruFocus values NOW at $243.65, suggesting a 43.3% undervaluation. The company has a GF Score of 88/100, indicating strong performance, but insiders have sold $1.94M in shares recently. ServiceNow specializes in cloud-based enterprise solutions with $10B in annual subscription revenue.

$NOWHigh

UBS raises ServiceNow stock price target to $150 on stable demand

UBS raised its price target on ServiceNow (NYSE:NOW) to $150 from $110, citing stable demand and improved Q3 2026 estimates. The stock is currently trading at $139.80, with a Fair Value of $164.41 according to InvestingPro. UBS expects normal Q3 earnings growth. Other analysts have also raised targets, with Stifel at $160, Cantor Fitzgerald at $174, and Needham at $155.

$GOOGLHighAI 9/10

The Biggest Buyers in Cybersecurity Now Are Not Cybersecurity Companies

Alphabet (GOOGL) acquired Wiz for $32B, boosting cloud security. ServiceNow (NOW) bought Veza and Armis for $8B, expanding incident management. Visa (V) agreed to buy BioCatch for $2.4B to enhance fraud detection. Accenture (ACN) acquired Dragos, runZero, and NetRise for $4.18B to expand OT security. All deals aim to integrate security into core businesses.

$NVOMed

Novo Nordisk A/S says FDA extends denecimig review

Novo Nordisk (NYSE: NVO) announced that the FDA extended its review of denecimig, a treatment for haemophilia A, due to ongoing manufacturing facility remediation. The company had expected a decision in Q3 2026 but received no new timeline. The delay does not affect Novo's 2026 financial outlook or other products. Denecimig received a positive opinion from Europe's CHMP on Sept. 17, with marketing approval pending. Novo's shares closed at $37.91 before the announcement.